Pharma Focus Asia

WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics

Monday, December 10, 2018

WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced today a strategic collaboration with Brii Biosciences (Brii Bio), an innovative biotechnology company operates in China and the US, focusing on accelerating innovation and optimizing access to serve the need of Chinese patients and public health, to discover and develop bispecific antibodies to treat infectious diseases and other immunologic disorders.

This collaboration will further integrate the advantages of the two companies and expedite the development of Brii Bio's pipeline. Under the terms of the exclusive research agreement, Brii Bio has the access to WuXi Biologics' entire antibody platform capabilities including the WuXiBody™ technology to discover novel bispecific antibodies. WuXi Biologics will also be the exclusive development and manufacturing partner of any novel bispecific antibodies discovered from the WuXiBody™ Platform.

"Discovery of novel immunotherapeutics modulating the host immune responses represents an untapped paradigm that may improve the treatment of infectious diseases," said Dr. Zhi Hong, Co-founder and Chief Executive Officer of Brii Biosciences, "WuXi Biologics has successfully grown and expanded its capability and capacity in biopharmaceutical, which will enable us to translate target insight to key therapeutic modalities and innovate in China for the world."

"We are pleased to enable Brii Bio in developing and manufacturing bispecific therapeutics through the proprietary WuXiBody™ Platform that tackles technical hurdles of bispecific platforms and tremendously reduces the cost of making these biologics, therefore offer novel treatments for unmet medical needs," said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics. "The collaboration is expected to develop and manufacture life-saving biologics targeting different diseases, and then benefit patients around the world."

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Asia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024Medlab Middle East 2024